Abstract
The skeletal muscle atrophy and sarcopenia are negative prognostic factors in the treatment of the diabetic aged-population. Insulin therapy stimulated protein anabolism in younger but not older patients and failed to prevent atrophy. The insulin- sensitizer glitazones are promising agents against atrophy but the un-favorable benefit/risk profile limits their use. Metformin is an AMPK agonist potentiating insulin actions in the adult human muscle, but not in the aged individuals. The AMPK agonists have the potential to induce atrophy. The KATP channel blockers such as the sulfonylureas and glinide may induce atrophy. Glibenclamide indeed induces atrophy in rat and in human. Within the glinides, repaglinide is the most potent atrophic agent “in vitro” in animals. The GLP-1 and incretins showed beneficial effects in skeletal muscle but their effects on the age-dependent muscle atrophy in human and animals are not known. The novel sodium glucose co-transporter inhibitors may not have been recognized as drug-induced atrophic/anti-atrophic effects. Here we reviewed the effects of the anti-diabetic drugs on the age-related muscle atrophy.
Keywords: Antidiabetic drugs, sarcopenia, skeletal muscle, aging.
Current Diabetes Reviews
Title:Effects of the Antidiabetic Drugs on the Age-Related Atrophy and Sarcopenia Associated with Diabetes Type II.
Volume: 10 Issue: 4
Author(s): Michela Cetrone, Antonietta Mele and Domenico Tricarico
Affiliation:
Keywords: Antidiabetic drugs, sarcopenia, skeletal muscle, aging.
Abstract: The skeletal muscle atrophy and sarcopenia are negative prognostic factors in the treatment of the diabetic aged-population. Insulin therapy stimulated protein anabolism in younger but not older patients and failed to prevent atrophy. The insulin- sensitizer glitazones are promising agents against atrophy but the un-favorable benefit/risk profile limits their use. Metformin is an AMPK agonist potentiating insulin actions in the adult human muscle, but not in the aged individuals. The AMPK agonists have the potential to induce atrophy. The KATP channel blockers such as the sulfonylureas and glinide may induce atrophy. Glibenclamide indeed induces atrophy in rat and in human. Within the glinides, repaglinide is the most potent atrophic agent “in vitro” in animals. The GLP-1 and incretins showed beneficial effects in skeletal muscle but their effects on the age-dependent muscle atrophy in human and animals are not known. The novel sodium glucose co-transporter inhibitors may not have been recognized as drug-induced atrophic/anti-atrophic effects. Here we reviewed the effects of the anti-diabetic drugs on the age-related muscle atrophy.
Export Options
About this article
Cite this article as:
Cetrone Michela, Mele Antonietta and Tricarico Domenico, Effects of the Antidiabetic Drugs on the Age-Related Atrophy and Sarcopenia Associated with Diabetes Type II., Current Diabetes Reviews 2014; 10 (4) . https://dx.doi.org/10.2174/1573399810666140918121022
DOI https://dx.doi.org/10.2174/1573399810666140918121022 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Skeletal Myoblasts for Heart Regeneration and Repair: State of the Art and Perspectives on the Mechanisms for Functional Cardiac Benefits
Current Pharmaceutical Design Is a "Mitochondrial Psychiatry" in the Future? A Review
Current Psychiatry Reviews Steatohepatitis in HIV-Infected Subjects: Pathogenesis, Clinical Impact and Implications in Clinical Management
Current HIV Research Sesamol Induces Apoptosis by Altering Expression of Bcl-2 and Bax Proteins and Modifies Skin Tumor Development in Balb/c Mice
Anti-Cancer Agents in Medicinal Chemistry Effects of Statins on Transplant Graft Arterial Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Endogenous Repair System of Oxidative Damage of DNA
Current Chemical Biology Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Treating Nonthyroidal Illness Syndrome in the Critically Ill Patient: Still a Matter of Controversy
Current Drug Targets Biomarkers of Atrial Fibrillation in Metabolic Syndrome
Current Medicinal Chemistry Obesity and Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Fractional Flow Reserve: Physiological Basis, Advantages and Limitations, and Potential Gender Differences
Current Cardiology Reviews Short-term RR-Interval Power Spectral Analysis as a New Tool to Stratify the Risk of Sudden Death in Various Cardiovascular Conditions
Vascular Disease Prevention (Discontinued) Genetics of Congenital Heart Disease
Current Cardiology Reviews The Variable Presentations of Glycogen Storage Disease Type IV: A Review of Clinical, Enzymatic and Molecular Studies
Current Molecular Medicine Green Tea Attenuates Cardiovascular Remodeling and Metabolic Symptoms in High Carbohydrate-Fed Rats
Current Pharmaceutical Biotechnology Getting to the Heart of the Matter: Exploring Opportunities for Gene Therapy Treatment of Dystrophic Cardiomyopathy
Current Gene Therapy Targeting microRNAs in Pathological Hypertrophy and Cardiac Failure
Mini-Reviews in Medicinal Chemistry DNAJ Proteins and Protein Aggregation Diseases
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Current Topics in Pharmacogenomics)
Recent Patents on Biotechnology Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology